Related Experiment Videos
How do we achieve optimal cardiovascular risk reduction?
1Weill Medical College of Cornell University, New York, New York 10021, USA. amg_editorial@med.cornell.edu
Insights
Optimizing coronary heart disease (CHD) risk requires better patient care and refined risk assessment. New guidelines improve risk calculation, identifying more patients for effective CHD prevention strategies.
Area of Science:
- Cardiology
- Preventive Medicine
- Lipidology
Background:
- Coronary heart disease (CHD) risk reduction is suboptimal in many patients.
- Current statin therapy, while effective, does not prevent all CHD events.
- Additional lipid targets beyond LDL cholesterol may enhance risk reduction.
Purpose of the Study:
- To highlight the need for improved clinical evidence application in patient care.
- To emphasize the importance of refining risk assessment for CHD.
- To discuss the role of updated guidelines in identifying at-risk individuals.
Main Methods:
- Review of clinical evidence regarding CHD risk factors and treatment efficacy.
- Analysis of limitations in previous global risk assessment measures.
- Introduction of revised National Cholesterol Education Program (NCEP) guidelines and the Framingham scoring system.
Main Results:
- Most patients are not achieving optimal low-density lipoprotein (LDL) cholesterol goals.
- Even with statin therapy, residual CHD events occur.
- Revised guidelines offer more precise risk assessment, identifying more patients for intervention.
Conclusions:
- Refined risk assessment is crucial for effective CHD prevention.
- Targeting multiple lipid factors may improve outcomes.
- Cost may influence treatment accessibility for lower-risk individuals.
Abstract:
Optimizing coronary heart disease (CHD) risk reduction requires the application of clinical evidence to patient care, as well as the refinement of risk assessment. Clinical evidence indicates that most patients are not treated to optimal low-density lipoprotein (LDL) cholesterol goals. Despite the efficacy of statin therapy in reducing the incidence of CHD, many treated patients still experience CHD events. Targeting other lipid factors such as high-density lipoprotein cholesterol and triglycerides may augment the risk reduction achieved by lowering LDL cholesterol. Refined global risk assessment can lead to more accurate determinations of absolute risk and to the identification both of high-risk patients needing aggressive intervention and intermediate-risk patients who appear to be at low risk. Previous global risk assessment measures failed to identify a substantial proportion of primary prevention patients who would benefit from therapy. However, revised guidelines issued by the National Cholesterol Education Program introduce new criteria for more precise risk assessment and advocate use of the Framingham scoring system to calculate absolute risk. Although intensified treatment is recommended for high-risk patients, cost considerations may limit drug therapy for some lower-risk individuals.